
The episode discusses the evolving management of ESR1-mutated metastatic breast cancer and the complexities in treatment decisions.
As the management of patients with ESR1-mutated metastatic breast cancer evolves,various questions have emerged in clinical practice. “It's a complex situation,” explainsHope S. Rugo, MD, division chief of breast medical oncology and the Women's CancersProgram director at the City of Hope Comprehensive Cancer Center in Duarte,California. She discusses how recent advances have changed treatment decisions withRobert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology atCedars-Sinai Cancer in Los Angeles. “I think it's important to keep in mind that today wejust have single-agent oral SERDs, and people like to give combinations,” Dr. Rugonotes. But what combinations to give and when remains unclear. “I think how we'regoing to decide is that we're going to wait and see what's approved and then look atpatients to try and figure out what to do,” she offers.
Guests: Hope S. Rugo, Robert A. Figlin
Organizations: City of Hope Comprehensive Cancer Center, Cedars-Sinai Cancer
Places: Duarte, California, Los Angeles
Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.